EA202090135A1 - NEW COMPOSITIONS OF 2- (IMIDAZOL-4-YL) ETHANAMIDE PENTANDIOVIC-1,5 ACID FOR TREATMENT AND PREVENTION OF VIRAL DISEASES - Google Patents

NEW COMPOSITIONS OF 2- (IMIDAZOL-4-YL) ETHANAMIDE PENTANDIOVIC-1,5 ACID FOR TREATMENT AND PREVENTION OF VIRAL DISEASES

Info

Publication number
EA202090135A1
EA202090135A1 EA202090135A EA202090135A EA202090135A1 EA 202090135 A1 EA202090135 A1 EA 202090135A1 EA 202090135 A EA202090135 A EA 202090135A EA 202090135 A EA202090135 A EA 202090135A EA 202090135 A1 EA202090135 A1 EA 202090135A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
imidazol
prevention
treatment
acid
Prior art date
Application number
EA202090135A
Other languages
Russian (ru)
Other versions
EA038170B1 (en
Inventor
Антон Петрович ПЕРЕВЕРЗЕВ
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA202090135A1 publication Critical patent/EA202090135A1/en
Publication of EA038170B1 publication Critical patent/EA038170B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области медицины, фармакологии и химико-фармацевтической промышленности, а именно к новым составам для лечения и профилактики заболеваний дыхательных путей, содержащим 2-(имидазол-4-ил)этанамид пентандиовой-1,5 кислоты и N,N'-бис-[2-(1Н-имидазол-4-ил)этил]пентандиамид, и/или их оптические изомеры, и/или их фармацевтически приемлемые соли, фармацевтической композиции на основе упомянутых составов, лекарственному средству на основе упомянутых составов или упомянутой фармацевтической композиции и готовой лекарственной форме на основе упомянутых составов, упомянутой фармацевтической композиции или упомянутого лекарственного средства. Изобретение также относится к применению упомянутых составов, фармацевтической композиции, лекарственному средству или готовой лекарственной форме для лечения и профилактики заболеваний дыхательных путей.The invention relates to the field of medicine, pharmacology and the chemical-pharmaceutical industry, namely to new compositions for the treatment and prevention of respiratory diseases, containing 2- (imidazol-4-yl) ethanamide of pentanedioic acid-1,5 acid and N, N'-bis - [2- (1H-imidazol-4-yl) ethyl] pentanediamide, and / or their optical isomers and / or their pharmaceutically acceptable salts, a pharmaceutical composition based on said compositions, a drug based on said compositions or said pharmaceutical composition, and a finished dosage form based on the aforementioned compositions, said pharmaceutical composition, or said medicinal product. The invention also relates to the use of said compositions, pharmaceutical composition, medicament or finished dosage form for the treatment and prevention of respiratory tract diseases.

EA202090135A 2019-09-12 2020-01-23 Pentandioic-1,5 acid 2-(imidazol-4-yl)ethanamide formulations for treating and preventing viral diseases EA038170B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019128667A RU2745265C2 (en) 2019-09-12 2019-09-12 Novel 2-(imidazol-4-yl)-ethanamide of pentandioic-1,5 acid compositions for treating and preventing viral diseases

Publications (2)

Publication Number Publication Date
EA202090135A1 true EA202090135A1 (en) 2021-03-31
EA038170B1 EA038170B1 (en) 2021-07-19

Family

ID=74873846

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090135A EA038170B1 (en) 2019-09-12 2020-01-23 Pentandioic-1,5 acid 2-(imidazol-4-yl)ethanamide formulations for treating and preventing viral diseases

Country Status (3)

Country Link
EA (1) EA038170B1 (en)
RU (1) RU2745265C2 (en)
UA (1) UA125151C2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4920974B1 (en) * 1970-06-01 1974-05-29
RU2141483C1 (en) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Peptide derivatives or their pharmaceutically acceptable salts, method of their synthesis, use and pharmaceutical composition
RU2665688C2 (en) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Dicarboxylic acid bisamide derivatives, their application, the pharmaceutical composition on their basis, methods for their production
RU2679636C1 (en) * 2018-10-29 2019-02-12 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" New method of the n,n'-bis[2-(1h-imidazol-4-yl)ethyl]malonamide obtaining

Also Published As

Publication number Publication date
RU2019128667A (en) 2021-03-12
RU2019128667A3 (en) 2021-03-12
EA038170B1 (en) 2021-07-19
RU2745265C2 (en) 2021-03-22
UA125151C2 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
EA201101518A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY
MX2012007410A (en) Novel antiviral compounds.
HN2011001358A (en) MODULATORS OF ARIL METHYL BENZOQUINAZOLINE POSITIVE ALLOSTERICS OF THE RECEIVER M1
BR112022003514A2 (en) Bifunctional brd9 degraders and their methods of use
UA107578C2 (en) COMBINED DIABETES THERAPY
MX2022005985A (en) Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof.
RU2012157328A (en) MEDICINAL PRODUCT FOR PREVENTIVE AND / OR THERAPEUTIC TREATMENT OF DEMENTIA BY ALZHEIMER TYPE
NI201300008A (en) THE NEW STABLE CONJUGATED POLYETHYLENE GLYCOL OF INTERFERON ALPHA, REPRESENTED BY A POSITIONAL ISOMER
BRPI0413062A (en) sulfonamide compounds, processes for obtaining their derivatives, their medicines and their uses
MX2021006724A (en) Haloallylamine compounds and application thereof.
EA202190544A1 (en) APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES
EA202190308A1 (en) APPLICATION OF DRUGS RILUZOLE FOR TREATMENT OF ALZHEIMER'S DISEASE
BR112019024804A2 (en) 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases
EA202090135A1 (en) NEW COMPOSITIONS OF 2- (IMIDAZOL-4-YL) ETHANAMIDE PENTANDIOVIC-1,5 ACID FOR TREATMENT AND PREVENTION OF VIRAL DISEASES
EP3919052A4 (en) Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
EA202191124A1 (en) DOSAGE FORM FOR TREATMENT AND PREVENTION OF INFLUENZA AND ARVI
IL307997A (en) Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
JP2023524229A (en) Compounds for the prevention and treatment of post-intensive care cognitive impairment and cognitive impairment due to dyspnea
MA58507A1 (en) Levilimab aqueous pharmaceutical composition
BR112022021105A2 (en) DOSAGE REGIME TO TREAT A CSF-1R MODULATED DISEASE
JOP20220045A1 (en) Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS
MX2021008329A (en) Prophylactic or therapeutic drug for neurodegenerative diseases.
DK2091520T3 (en) ORAL DOSAGE FORM CONTAINING TRISUBSTITUTED GLYCEROL COMPOUNDS
HU227813B1 (en) Pharmaceutical composition for the treatment of psychosis